6733.TWO BioGend Therapeutics Co., Ltd.

Healthcare Biotechnology Taiwan OTC Exchange
21.00 TWD
Close of Nov 6, 2026
20.15 42.00
Market cap
TWD 2.82B
P/E
-
P/B
2.77x
ROE
-7.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6733.TWO undervalued?

Graham number

The Graham number of BioGend Therapeutics Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioGend Therapeutics Co., Ltd. fundamental analysis

No fundamental analysis for BioGend Therapeutics Co., Ltd. yet.

BioGend Therapeutics Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd. engages in the research and development, and sale of orthopedic medical devices and related products. The company offers RevoCart, an autologous cartilage repair system; and SoufCut, an autologous adipose tissue collection system. It develops BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articaular cartilage. The company operates in Taiwan, Hongkong,…

Full company profile